Increased full-year 2010 expectations after strong first-half performance

The strong sales and earnings growth in the first half of the year came from higher demand in the enzyme business and a continued good cost development across the organization. The strong growth was also the result of a challenged first half in 2009.

Based on the first-half performance and currencies that have developed slightly favorably since previous guidance, sales are now expected to grow by 10 – 12 percent in DKK (7– 9 % organically). EBIT is expected to grow by 20 – 22 percent, and the EBIT margin is expected to be in the range of 21 – 22 percent. Net profit is expected to grow by 22 – 24 percent, investments are now expected to be in the range of DKK 1,150 – 1,250 million, and free cash flow before acquisitions is expected at DKK 800 – 900 million.